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FINAL DEFENSE
Abstract
Introduction: Patients that require medication assisted treatment for opioid addiction can have their
treatment delayed through the prior authorization process. A prior authorization is required by many
insurance companies and can cause lengthy delays before the drug is approved. The two drugs that were

considered for this project were Suboxone® (buprenorphine/naloxone) and Sublocade® (buprenorphine).
These drugs are used for the treatment of opiate addiction. The proposed solution to the problem was to
use quality improvement methods to implement a tracking and tickler system to improve the approval
time from the insurance company.
Objectives: The project goal was to decrease the amount of time from the time the prescription was
written until the medication assisted treatment was initiated.
Methods: This project used quality improvement methods to review pre and post intervention data. The
setting is a single physician addiction medicine clinic.
Results: There were no changes in the amount of time between prescribing and start of treatment with the
tickler and tracking system. When drugs are added to the insurance company’s formulary, prior
authorizations are not required. Any improvement in the time from prescribing to medication start was
related to changes in the insurance company’s formulary.
Conclusions: Tracking the prior authorizations did not change the time frame of which they were
completed.
Implications: With the opioid epidemic, patients are dying daily across the U.S. due to drug overdose.
Patients that experience a gap in their treatment are at a higher risk for relapse and possible overdose.
The insurance industry needs to improve their process for approving medications for patients being
treated for opioid addiction.
Keywords: Suboxone® (buprenorphine/naloxone), Sublocade® (buprenorphine), prior authorization,
treatment delays, addiction medicine, opiate addiction.
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Prior Authorizations and Continued Treatment in Addiction Medicine
In 2017, the United States Department of Health and Human Services declared a public
health emergency related to the opioid crisis (HHS.gov, 2019). As of January 2019, it has been
estimated that 2.1 million people abuse opioids in America and 130 people die every day related
to overdoses of opioids (HHS.gov, 2019). These numbers are staggering. To help treat the
disease of opioid addiction, medication assisted treatment has been shown to be safe and
effective (SAMHSA, 2019).
Buprenorphine is one of the many drugs available to treat opioid addiction.
Buprenorphine is an opioid partial agonist which means that it can produce many of the same
effects as opioids. However, the effects are weaker. Buprenorphine can be taken transmucosal
in a film form and mixed with naloxone (brand name for the combination medication is
Suboxone®). Adding naloxone helps to decrease the likelihood of diversion and misuse of the
drug (SAMHSA, 2019). If the film is altered or broken down to be used in the injectable form,
the naloxone effect dominates and can bring on opioid withdrawals (SAMHSA, 2019). Once a
patient is stable on buprenorphine/naloxone, they can be switched to a long acting injection of
buprenorphine (brand name Sublocade®). The medication is injected once every 28 days by a
certified provider.
In order to treat the patient with buprenorphine or buprenorphine/naloxone, the provider
must have a special DEA number which can only be obtained after taking a 24-hour training
course (SAMHSA, 2019). Once completed, the provider is limited in the number of patients that
they can treat with buprenorphine (SAMHSA, 2019). The law limits providers to 30 patients in
the first year after waiver certification is completed. When the law was initially put into place
back in 2005, the limit of 30 patients was a fixed limit. In 2006, the Food and Drug Association
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(FDA) increased the number of patients a provider could see to 100 after one year of
certification.

In addition to the limited number of prescriptions available to provide treatment

for patients with opioid addiction, the insurance industry has a significant amount of control over
how quickly treatment will be authorized and paid for. One concerning delay is the requirement
for a prior authorization for medication assisted treatment. The purpose of this project is to
develop and implement an evidence-based practice improvement project to improve the process
of prior authorization completion.
Assessment of the Organization
An organizational assessment was conducted in a single-physician clinic specializing in
the treatment of patients struggling with addiction. In addition to the physician, business is
conducted with an office manager. The organizational assessment included both the clinical and
the non-clinical settings. In this assessment, the Burke and Litwin model was utilized as the
framework for the organizational assessment (Burke & Litwin, 1992). All elements of the model
are reviewed with an explanation of the corresponding information gathered from the clinical
practice. After that, a Strengths, Weakness, Opportunities, and Threat (SWOT) analysis was
used to organize the findings within the organization (William and Anna Newman Library,
2018). Lastly, an analysis of the organization assessment, the clinical problem and conclusions
are provided.
Organizational Assessment Tool: Burke and Litwin Model
The Burke and Litwin organizational performance and change model illustrates the
foundation of 12 factors which are: external environment, mission and strategy, leadership,
organizational culture, structure, management practices, systems, work unit climate, task and
individual skills, individual needs and values, motivation, individual and organizational
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performance (Reflect & Learn, n.d., Stone, Brown, Smith, & Jacobs, 2018, and Burke & Litwin,
1992). The 12 factors are further divided into two groups: transformational and transactional
dimensions. Figure one illustrates the Burke and Litwin model. The transformational factors are
more consistent with leadership and are located at the top of the figure. In contrast, the
transactional factors which are located on the bottom of the model (see figure 1) include:
management practices, structure, systems, climate, motivation, task and skills abilities, and needs
and values which are more consistent with management (Stone, et al. 2018, Burke & Litwin,
1992).
The reliability and validity of the Burke-Litwin organizational assessment is well
documented by Stone in 2015 (Stone, et al., 2018) and the validity of the tool was noted to be the
“strongest” as supported by Burke (2018) and Burke and Litwin (1992). Stone also notes that
“structural validity through factor analysis by Anderson-Rudolf (1996), Fox (1990), and Stone
(2010) (Stone, et al. 2018). Figure one best demonstrates the complexity as the arrows go in
both directions which reflects that a change in one area will influence another. This is also called
a casual model (Burke & Litwin, 1992).
Components of the Burke and Litwin Model: Transformational
Transformational factors include external environment, mission and strategy, leadership,
and culture (Burke & Litwin, 1992). Changes in these areas are likely to be caused by external
environmental forces. When an organization undergoes transformational change, new behaviors
must be accepted for an organization to be successful (Burke, 2017).
External Environment
Burke and Litwin defined the external environment as “any outside condition or situation
that influences the performance of the organization” (Burke and Litwin, 1992, p. 531). The
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physician’s patient population is mostly self-referred. If a patient is referred by another
physician or counselor, the office manager awaits a call from the patient to schedule as it shows
motivation towards treatment (personal communication, XXX, 2018). Some of the referrals
come from the drug court. Drug court is a one to two-year program that is provided through the
county judicial system. This program focuses on individuals who have been arrested for
misdemeanor and felony drug and drug-related offenses who have an abuse history. Individuals
that participate in the drug court program have additional responsibilities as required by the court
(61st District Court Drug Court, N.D.). Another referral base is from an organization that works
with medical providers that have become addicted. This organization allows employees that
have addiction to keep their job with the understanding that they follow the treatment plan as set
forth by the physician.
A significant outside influence that the addiction clinic deals with is the insurance
industry. Currently, the clinic uses a private billing service biller, but it is up to the organization
to get authorization to treat the patient. If the patient has insurance other than Medicaid, the
office manager collects a co-pay. Currently, the clinic has no process to determine the actual copay amount due from a patient based on the patient’s reimbursement source; this causes the
office manager to be unsure of the amount of money to collect (personal communication, XXX,
2018). For follow up visits, the non-Medicaid insured patients are informed by text, prior to
their visit of the amount of money they owe for payment at the time of the appointment. Some
insurers, such as Priority Health, also require prior authorization for the medications that are
typically prescribed by the physician to treat addiction.
Buprenorphine/naloxone, otherwise known as Suboxone® is a medication that the
physician primarily prescribes for patients being treated for opioid addiction. To prescribe
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buprenorphine, the provider must complete the waiver process set forth by the American Society
of Addiction Medicine (ASAM). Currently, the requirement is 24 hours of education that
reviews the national guidelines for treatment of these patients which includes the requirements
for prescribing of buprenorphine to be granted the waiver. With these requirements, many
insurance companies will require a prior authorization, just to verify that the physician has
obtained the appropriate waiver. Once the waiver is verified, they will issue the authorization
and cover the medication. This multi-step process can result in delays in starting treatment. The
prior authorization delay is problematic for patients as the goal of therapy is to start
buprenorphine when they are in the early phases of withdrawal. The time frame between the
abused medication stopping and withdrawal symptoms vary. Heroin withdrawal can start within
6 hours of the last use whereas methadone withdrawal symptoms may not present for upwards of
96 hours (Prunty, 2016). Withdrawal symptoms that may be present include: agitation, anxiety,
dysphoria, insomnia, and temperature inability (Prunty, 2016).
Prior authorizations are granted for a specific period depending on the dose prescribed.
Each insurance company has their own guidelines for the length of approval. When the approval
is close to expiration, the office manager must then complete another prior authorization where,
at times, the insurance company may request additional information to continue to pay for the
medication. This can again, result in a delay or gaps in treatment.
Mission and Strategy
A mission statement is a written statement of what the organization believes is the
purpose of the organization. Per the physician, the mission statement of the practice is “I have
made my life, my career, and my passion about caring for, and protecting the rights of
individuals in our society who have been marginalized, shamed, blamed, and even punished for

FINAL DEFENSE

10

their disease- alcoholism, drug dependence/addiction, and mental health disease” (XXX, 2018).
From observation in the clinic and outside of the clinic, the physician and the office manger live
this mission statement every day.
Leadership
Burke and Litwin defined leadership as “executives providing overall organizational
direction and serving as behavioral role models for all employees” (Burke & Litwin, 1992). This
organization has a physician and an office manager. The physician is the leader of the
organization from a clinical standpoint and the office manager is the lead for business
management. Overall, the office manager leads the practice and takes responsibility for all
aspects of the day to day activities that make the practice successful. She ensures that the
physician has everything that she requires to be successful. The purpose of this organization
assessment is the one-physician clinic. The other activities as an employed physician are outside
the scope of this assessment.
Organization Culture
Organizational culture reflects how things are done in the clinic (Burke & Litwin, 1992).
This includes rules (norms) of the organization which can be further be broken down to explicit
and implicit rules (Burke, 2017). This clinic has few written policies but one of their policiesrelated to patients being on time- is strictly enforced. Patients are required to be 10-15 minutes
early for their scheduled appointment. This provides time for the required urine drug testing and
vital signs to be completed as well as the collection of co-pays.
This milieu of this office is relaxed. The physician and the office manager support and
encourage each other on a personal and professional level and both manage the clinic. The
physician and office manager dress casually and their office interactions are casual. This relaxed
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presence appears to make patients, new and established, feel more comfortable with coming in.
The office also has two therapy dogs that are allowed to come and go during the office visits.
Components of the Burke and Litwin Model: Transactional
Transactional components include management practices, structure, systems, task
requirements and individual skills, work unit climate, individual needs and values, motivation,
and individual and organizational performance. The components concern the day-to-day
operations or the organization and drive continuous improvement rather than reactionary
improvement (Burke, 2017).
Management Practices
This category reviews what the managerial practices are from day to day (Burke, 2017).
In 1992, Burke and Litwin defined it as “what managers do in the normal course of events to use
the human and material resources at their disposal to carry out the organizations strategy” (Burke
& Litwin, 1992). The office manager is available Monday through Friday from 9AM-5PM. The
physician makes herself available to the patients 24 hours a day seven days a week.
The office manager’s role requires independence in the day to day tasks regardless of the
place of work. Patients are checked in by the office manager and she is responsible to ensure
that each patient completes a drug screen at the beginning of their appointments. Urine drug
screen results are reviewed with the patient at their next appointment. Additional tasks that the
office manager completes in this setting include: prior authorizations, scheduling appointments,
sending reminders for appointments, checking MAPS (Michigan Automated Prescription
System), answering the phone and texts throughout the day, and keeping up with all of the
paperwork and scanning of paperwork to the electronic health record. She also is responsible for
keeping the financial records up to date and ensuring that the bills related to the clinic are paid.

FINAL DEFENSE

12

Collaboration and communication are key between the physician and office manager,
which has allowed for many of the recent clinic changes. Some of the recent changes include: 1)
the change of office manager, 2) the addition of seeing telehealth patients in some rural areas
and, 3) working with an organization that provides care to the underserved.
The physician has a strong desire to treat patients regardless of their insurance coverage.
The reimbursement from Medicaid is very low and the physician must limit the number of
patients to be financially sustained. The reimbursement from Medicaid is lower than what is
reimbursed by private insurance companies. Accepting a patient with Medicaid dictates that the
provider will accept the reimbursement from Medicaid. The provider cannot bill the patient for
the difference. In the past year, the physician began to work with an organization two days a
week that provides mental health services to the underserved. This enabled her to expand the
number of patients that had Medicaid coverage. If a patient has Medicaid and lives in Kent
County, they can be evaluated at an off-site clinic. Patients that have Medicaid from any other
county are treated in the physician’s office.
Structure
Burke defines structure as “arrangement of organization functions (for example
accounting, manufacturing, human resource management) and operational units (for example the
western region) that signify levels of responsibility, decision-making authority, and lines of
communication and relationships that lead to implementation of the organization’s missions,
goals, and strategy” (Burke, 2017, p. 281). This is a small organization that is led by a physician
and office manager. The billing staff is off site and works one day a week for the clinic patients.
This physician has no back-up and has accepted responsibility for after-hours patient call every
day.
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Systems
Systems refer to policy and procedures (Burke, 2017). Policy and procedures support the
organization members (and key stakeholders) and defines jobs and role responsibilities (Burke,
2017). The clinic has a policy for banking and payroll with a page of policies that are mixed
together. This page reflects the policy related to appointment scheduling.
Systems can also encompass information technology (Burke, 2017). In the clinic, the
physician uses Practice Fusion® software for the EMR. Practice Fusion® software has built a
variety of templates for documentation purposes for use by providers but are cumbersome for the
physician in the clinic. The physician can build her own templates for documentation. The
process to build the templates takes an understanding of the software that requires additional
time and training that the physician has not been able to accomplish at this time.
The physician uses Google docs for patient tracking. Google docs is also used for
keeping track of patient accounts. The office manager is unsure if the Google software is
HIPAA compliant (personal communication, XXX, 2018).
Task Requirements and Individual Skills
Task requirements and individual skills is ensuring that the right person is doing the right
job (Burke, 2017). Burke goes on to further define it as a “job-person match: the degree to
which there is congruence between the requirements of the job, role, and responsibilities and the
knowledge, skills, and abilities of the individual holding the job” (Burke, 2017). The physician
is licensed to practice and has the certification required to prescribe buprenorphine.
The office manager, admittedly, did not have management experience when she started
working in the office. Upon completing a google search, the recommended education for a
medical office manager ranges from high school diploma to a bachelor’s degree depending on

FINAL DEFENSE

14

the size of the practice. The office manager does have a degree in psychology and she is
continuing her education in health. She is familiar with the clinic as she is a family member to
the physician (personal communication, XXX, 2018).
Work Unit Climate
The work climate is the perception of the employees in a work unit. These perceptions
can include: clarity of what is expected of the person/team, how the performance is recognized,
and how supported the person feels (Burke, 2017). The two employees in the clinic support each
other both personally and professionally. Together, they make all the decisions for the clinic and
the climate of the clinic is relaxed and positive.
Individual Needs and Values
Individual needs and values are the employee’s perception with job satisfaction (Burke &
Litwin, 1992). The physician reported that in 2016 she made under $10,000 per her W2 but that
she “wouldn’t change a thing”. She states that when patients overcome their addiction, she feels
fulfillment that money cannot give her. The physician and office manager take pride in their
work and want to be able to do more but find that there isn’t enough time each day to do so.
Motivation
Motivation is the desire to move towards the goals of the organization and act on that
desire (Burke, 2017). The physician is motivated by the success of the patient in overcoming
their addiction. The patients present to the office going through withdrawal from substances
such as opiates, heroin, and cocaine. She also treats patients that have an addiction to alcohol.
The physician is motivated to get the word out to the community about the treatment of
addiction. The physician is active in the local community and lectures multiple times each
month on opioid addiction.
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Individual and Organizational Performance
Burke (2017) reported that performance is “defined and measured by indices such as
productivity, customer satisfaction, quality of product or service, and profit or earnings per
share”. This clinic is productive, and it is thought to be related to a strict policy for appointment
scheduling. The physician will not see a patient that arrives late. A patient that does not arrive
at least 10 minutes prior to their appointment with the physician will be rescheduled. This can be
problematic for patients as their medication for their addiction is prescribed for the days until the
next office visit. The physician is productive in her visits and ensure that they do not go over the
time allotted. New patients are allowed an hour and return patients are allowed 20 minutes. This
is an area that patients have difficulty with honoring.
Customer satisfaction is another area that could be eventually improved upon. The clinic
does not provide patients the opportunity for patient satisfaction surveys. Some websites do
allow for online reviews of providers and at this time, the reviews are not all good.
Ethics and Protection of Human Subjects
An application for review and approval or exemption of this project was submitted to the
Grand Valley State University Institutional Review Board. Beyond further planning, no project
activities commenced until the review was completed and Board approval or exemption is
granted. The purpose and scope of this project were limited to implementation of a quality
improvement project. No patient identifiable information was collected. No physical, social,
psychological, legal, or economic threats to patients were associated with this project. As such,
the impact of the project posed minimal or no risk to participants. All members of the team
completed human subject’s protection training via the Collaborative Institute Training Initiative
and their interactions with patients were guided accordingly.

FINAL DEFENSE

16

Stakeholders
The clinic has key stakeholders that are involved with and were affected by any practice
change. The main stakeholder is the practice owner, the physician. In addition, the office
manager, billing coordinator, and patients have the potential to be affected by practice change. If
this quality improvement project works, we should be able to improve the lives of the patients
served by decreasing the time between treatment being prescribed and started.
SWOT
A SWOT analysis is a tool that analyzes an organization in four categories: strengths,
weaknesses, opportunities, and threats (William and Anna Newman Library, 2018). Gomer and
Hille defined a SWOT analysis as “a methodological tool designed to help workers and
companies optimize performance, maximize potential, manage competition, and minimize risk”
(N.D., p.1). A SWOT analysis can be used on companies large and small (Gomer and Hille,
N.D.). A benefit of a SWOT analysis is that it can help to understand the practice better while
pointing out opportunities for deterring threats. A downside to a SWOT analysis is that it is not
meant to provide solutions when problems are identified (William and Anna Newman Library,
2018).
Strengths
Some of the strengths of this organization include the physician’s passion about working
with this population. She makes herself available to her patients’ day and night so that she is
able to provide support at any time. Another strength is that the office manager and the
physician live in the same home and are related. This could also be considered a weakness
depending on the relationship between the two; at this time, the relationship is strong and
nurturing. Nationally, the opioid crisis is a popular topic and a priority public health crisis with
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limited provider availability to prescribe the medications used to treat opioid addiction. While
the physician states that this is a weakness of the medical community, it does ensure a continued
referral base.
Weaknesses
A significant weakness of the clinic is the limited written policy and procedures. Another
weakness includes only having one provider with no back up in place. This limits the provider’s
ability to take time off from caring for her patients. An additional weakness is related to the time
it takes to complete and keep up with the prior authorization process for patients’ treatment.
Finally, the EMR that is being used in the clinic may not be being used to its full capacity which
can have direct impact on time management.
Opportunities
An opportunity for the clinic is to create and implement policies and procedures; this
would ensure consistency in practice and adherence to regulations. Another opportunity would
include hiring an advanced practice provider to assist the physician in providing care to patients
and giving some time off by taking after hour calls. An opportunity would be to assess the
patient’s satisfaction in a formal fashion. An opportunity that may improve the patient’s
satisfaction would be to change the office policy for appointment scheduling.
Threats
Competition is a threat to this small clinic. To obtain the certification for prescribing
buprenorphine is not difficult and can usually be completed in less than a weekend. The more
providers being able to do this could limit the number of patients that are seen in the clinic.
Another threat to patients is changes to the affordable care act. Patients with mental illness,
including addiction, may have difficulty obtaining a job that has health insurance coverage. At
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this time, the affordable care act provides protection to patients, but this could change due to
changes in the political arena.
Clinical Practice Question
The practice that the organizational assessment was completed in is new and provides
care that cannot be found in most primary care offices. This organizational assessment has
identified multiple areas where the office could grow and improve. For the purpose of this

project, the clinical question chosen is: Can a systematic and evidence-based method improve the
timeliness of prior authorizations for patients’ addiction treatment medications?
Review of the Literature
Method
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guideline served as the framework for this review (Moher, Liberati, Tetzlaff, Altman, &
PRISMA Group, 2009). A comprehensive electronic search was conducted in the Cochran,
CINAHL, Google, Google Scholar, and PubMed and was limited to reviews in the English
language during the period of 2008 to 2018. The criteria for inclusion was studies that reviewed
policies and addiction medicine. Studies from prior to 2008 were included to review the length
of time this problem has existed. Keywords were prior authorization, addiction, addiction
medicine, mental health.
Summary of Results
The search yielded 23 PubMed reviews. No duplicates were found. Each review was
screened using inclusion and exclusion criteria according to PRISMA criteria (Moher, et al.,
2009). Review of titles and abstracts results in removal of six articles that did not meet the
inclusion criteria. In addition, nine articles were excluded after in-depth examination of content,
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as did not meet inclusion criteria. The remaining eight articles were included in this review.
Results
Access to care. The number of patients receiving treatment for substance use disorders
have been consistently very low. The biggest reasons that are reported by patients include cost
and access to treatment. Prior authorizations were listed as a barrier related to access to
treatment (Reif, et. al., 2017).
Currently, the Food and Drug Administration (FDA) has approved methadone,
buprenorphine, and naltrexone for the treatment of opioid use disorder (Huskamp, Riedel, Barry
& Busch, 2018). In office-based opioid use disorder treatment, experts agree that the
recommended drug is buprenorphine/naloxone preparations (Huskamp, Riedel, Barry & Busch,
2018). In a study that compared the Marketplace Insurance plans in 2017, it was found that 14
percent of the plans did not cover any formulation of buprenorphine/naloxone and only 10
percent will cover the extended release injectable buprenorphine (Huskamp, Riedel, Barry &
Busch, 2018).
When comparing state Medicaid plans, every state had buprenorphine on their drug list
but every single one of them imposed some type of utilization limit (Andrews, et. al., 2019). The
limitations included requiring co-pays, annual limits, or prior authorizations for buprenorphine
(Andrews, et. al., 2019). These limitations can have a negative effect on a provider being willing
to prescribe any form of buprenorphine (Andrews, et. al., 2019).
The effects of a treatment delay for patients with opioid use disorder can result in relapse.
The state of Massachusetts Medicaid program attempted to implement a stricter prior
authorization criterion for patients that were on high doses are buprenorphine (defined as greater
than 24mg daily) in order to save money. The study unfortunately noted a significant increase in
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patient relapses after full implementation of prior authorization requirements (Clark, Baxter,
Barton, Aweh, O’Connell & Fisher, 2014).
Provider burden. In 2010, the American Medical Association (AMA) completed a
survey of over 2,400 physicians to review their experience with prior authorizations. Two-thirds
of the physicians reported that they had to wait several days to receive a prior authorization for
drugs and 10 percent reported waiting more than a week (AMA, 2015). It is estimated that
interactions with the insurance company costs $82,975 annually per physician. The American
Medical Association estimates that close to 20 hours a week can be taken up by the medical
office staff to complete prior authorizations (AMA, 2015). These hours are not reimbursed by
the insurance industry and disrupt the workflow in the office, thus reduce the time that a
physician is able to spend with patients (AMA, 2015).
Recommendations to reduce prior authorization burden. The American Medical
Association has made recommendations to reduce the burden of prior authorizations (PA) on
practice.
1. “Check PA requirements before providing services or sending prescriptions to the
pharmacy.
2. Establish a protocol to consistently document data required for PA in the medical
record.
3. Select the PA method that will be most efficient, given the particular situation and
health plan’s PA options.
4. Regularly follow-up to ensure timely PA approval.
5. When a PA is in appropriately denied, submit an organized , concise and wellarticulated appeal with supporting clinical information” (AMA, 2015, p. 2-5).
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Another recommendation that was presented in the evidence was that the insurance company
needs regulation regarding the amount of time that they take to respond to prior authorizations
(Andrews et. al., 2019). The literature reviewed regarding buprenorphine and prior authorization
consistently recommends that the limitations be lifted by the insurance industry (AndrakaChristou & Capone, 2018). The insurance industry’s recommendation is for the provider to
increase office support to complete the prior authorizations (Huhn & Dunn, 2017).
Discussion
In the past, treatment for mental health services, including addiction medicine, have been
more limited than treatment for medical services (Horgan, et. al., 2015). In 2008, the Mental
Health Parity and Addiction Equity Act was enacted to equalize coverage in mental health
(Horgan, et. al., 2015). Researchers compared the coverage pre and post enactment and
unfortunately, they did not find a significant change in access to care nor reimbursement. They
found that insurance companies continued to delay payment for care, thus delaying treatment for
patients through other techniques such as utilization management and “selective contracting with
providers” (Horgan, et. al., 2015, p. 168). Another technique that insurance companies use is to
place medications on different tiers that represent the amount of money that they will reimburse,
leaving the patient to provide the remaining. Many times, the medication that is covered without
a prior authorization is not the most evidenced based treatment (Reif, et. al., 2017). The prior
authorization process in and of itself can delay treatment. Knowing that relapses are common in
patients that struggle with addiction, delays can be catastrophic in the recovery process (Reif, et.
al., 2017).
The literature that reviewed the state Medicaid systems found that each state had their
own requirements for approval of medication assisted addiction treatment (Andrews, Abraham,
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Grogan, Westlake, Pollack, Friedmann, 2019). In a study completed in 2015, it was noted that
48 of the 51 programs evaluated across the United States required prior authorizations (Mark,
Lubran, McCance-Katz, Chalk & Richardson, 2015) even though it was noted in their
recommendation that buprenorphine/naloxone is the medication of choice for opioid use
disorder.
The literature presented evidence that providers avoid prescribing buprenorphine in the
treatment of addiction related to the burdensome process to obtain prior authorizations
(Andrews, et. al., 2019). The more generous the state is to cover buprenorphine without
significant restrictions, the more likely a provider is to prescribe (Andrews, et., al. 2019).
“Considering that approximately 60% of the nation’s 14,500 addiction treatment programs are
operating in states requiring prior authorization, the dampening effects of these policies on
buprenorphine availability may be wide reaching” (Andrews, et., al. 2019).
In the review of the literature, a significant amount of information is found stating that

the prior authorization process is a barrier to treatment for patients with opioid use disorder. The
prior authorization process is also a burden to providers and their office staff. Unfortunately,
there is not a significant amount of information to guide the prior authorization process to get
these medications approved timely. For patients being treated for opioid addiction, barriers to
treatment can be deadly. This needs to change.
Project Plan
Purpose of Project and Objectives
The purpose of this project was to improve the time and tracking related to the
completion of prior authorizations. In general, prior authorizations are granted for a specific
time frame and if not renewed prior to the expiration date, a patient’s treatment could be denied
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coverage resulting in treatment delays (personal communication, XXX, 2018). A secondary
purpose of this project is to assist the mental health office with a starting point for their policies
and procedures. The provider was practicing without a formal set of policies and procedures.
Design for the Evidence-based Initiative
Utilizing models to guide change can be helpful. “A framework can be used to connect
all the important aspects of the project” (Moran, Burson & Conrad, 2017, p. 258). The theory
that was chosen to guide this initiative was Lewin’s change theory.
Lewin's change theory
Lewin’s change theory uses the image of an ice cube as the current state. Once an
organization desires to undergo a change, the ice cube is thawed (unfreezing). After the change
is implemented, the fluid is then re-frozen into a different shape to represent the change. The
MindTools team feels that this represents that change is common and something that occurs
quickly (N.D.).
In the unfreezing step of Lewin’s change theory, the organization needs to review the
status quo and determine if change is necessary. It is during this step that the attitude of “this is
how we have always done it” is broken (MindTools, N.D.). Allowing the team to re-examine
how things have been done and being part of the team to create change is thought to be
imperative to successful change (MindTools, N.D.). The unfreezing step was completed prior to
the proposal defense. The office manager was ready to make a change as the prior authorization
process was her responsibility. The office manager was instrumental in identifying the need for
a new process and had the support of the physician in making changes as necessary.
Change is the second step in Lewin’s change theory. This step happens slowly as
“people need time to embrace new direction” (MindTools, N.D.). Change for some can be
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difficult and to assist the team with getting on board, they need to understand how the change
will benefit them. Communication is of great importance during this phase (MindTools, N.D.).
Rumors can arise during change and being open and honest during communication will help to
decrease the chaos from rumors. Empowering and involving those who will be directly affected
by the change can also help to make the change successful (MindTools, N.D.).
The implementation of the project was messy. Many ideas were shared during the
proposal defense that could help the office manager in being more efficient with the prior
authorization process. One of those ideas was to provide the patients with the phone number
from the drug manufacturer and specialty pharmacy as they could receive phone calls from each.
This idea was added early in the hopes that the delay that the office was experiencing related to
the patients being contacted could be diminished. The office manager stayed in close contact
with the DNP student in addition to reaching out to the drug manufacturer for additional help
once the preliminary data wasn’t looking hopeful.
Finally, re-freezing is the third step in Lewin’s change theory. In this step, the team has
embraced the new way of practice and the period of change has stabilized (MindTools, N.D.). It
has been questioned if stabilization should be obtained as change if ever present, but Lewin’s
theory feels that stabilization allows for the team to know how things are supposed to be prior to
the next change (MindTools, N.D.). Re-freezing was not able to be completed related to
changes that occurred in the office. The changes are explained later in this document.
Setting
The setting this project took place is a one-physician clinic that provides care for patients
struggling with addiction. This office has a manager that assists the physician with clerical
duties in addition to some clinical duties to prep the patients for their visit with the physician.
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This project was also completed away from the office setting for the drafting of the policies.
This office sees patients two days a week. The physician and owner expressed support for this
initiative.
Participants
Participants that were involved in the project include the physician and the office
manager.
Model Guiding Implementation
A conceptual framework is similar to a map for guiding a project (Moran, Burson, &
Conrad, 2017). Kotter’s model for change will guide this implementation. Kotters model for
change was created based on John Kotter’s experience. Kotter’s change model includes the
following eight steps for change:
1. Establish an urgency about the need for the change. Kotter states that “successful change
efforts must begin with individuals and groups evaluating a company” (Applebaum,
Habashy, Malo, Shafiq, 2012, p.767) and urges the use of outside influences to complete
this step (Applebaum, Habashy, Malo, Shafiq, 2012).
2. Create a guiding coalition. According to Kotter, no one person can manage a change
process in an organization (Applebaum, Habashy, Malo, Shafiq, 2012). The coalition
team should include positional power, expertise, credibility, and leadership (Applebaum,
Habashy, Malo, Shafiq, 2012).
3. Develop a vision and a strategy. The first step of the change process after the team is
created is to formulate the vision. A clear vision can help to drive the objectives for the
change and provide direction (Applebaum, Habashy, Malo, Shafiq, 2012).

FINAL DEFENSE

26

4. Communicate the change vision. Communication of the change vision can “reduce
uncertainty, decrease ambiguity and can even affect the type of positive or negative
responses to the change” (Applebaum, Habashy, Malo, Shafiq, 2012, p. 770).
5. Empower broad-based action. Employees are more likely to embrace new ideas after
communication across the organization, however, employees may need help to get rid of
obstacles to the change vision (Applebaum, Habashy, Malo, Shafiq, 2012). Kotter
reports that the most common obstacles organizations face during change are: structures,
skills, systems, and supervisors. “Kotter stresses the pivotal role of training in the
empowerment process” (Applebaum, Habashy, Malo, Shafiq, 2012, p.772).
6. Generate short term wins. Seeing the change happen and watching it work can help the
organization obtain its longer-term goals (Applebaum, Habashy, Malo, Shafiq, 2012).
Celebrating the change as it is occurring can help to keep the momentum going.
7. Consolidate gains and produce more change. Throughout the change process, the
organization is encouraged to continually evaluate the change. During the process,
changes can regress back if the team does not remain focused on the vision (Applebaum,
Habashy, Malo, Shafiq, 2012)
8. Anchor new approaches in the corporate culture.
Implementation Steps and Strategies
1. Complete proposal and acceptance for the project by faculty at GVSU and stakeholders at
the organization by January 11, 2019. The proposal defense was completed as scheduled.
Multiple interventions were discussed during the proposal.
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2. Begin observation and time tracking of prior authorizations the week of January 14,
2019. Data was collected with the office manager related to new patients/prescriptions
and renewal of expiring prior authorizations as needed.
3. Chart review and data was collected with dates to include October 2018-January 11,
2019.
4. Creation of policy and decision was made to assist with how to best track prior
authorizations with the current tools available to the practice.
5. Obtain formal commitment from the office manager for the continuation of the tracking
tool for prior authorizations. This commitment may also pertain to the off-site clinic that
the physician currently sees patients with local county Medicaid insurance coverage
6. Present the electronic and written policy and procedure to the organization in May 2019
regarding the completion of prior authorizations. As the project was being completed,
patient need outweighed the need for the project and the office manager completed what
needed to be done to get the patient’s medications authorized. This may have resulted in
additional calls to the insurance company and the specialty pharmacy as appropriate.
Measures
The office manager will observe and track the time that she requires for completion of
prior authorizations. Data that will be collected includes:
•

Date prescription is written by the physician

•

What drug is being prescribed
o Buprenorphine or buprenorphine/naloxone

•

What type of insurance the patient had at the time of the medication prescription

•

Date of initial contact with the insurance company (initiation of prior authorization)
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o Dates of correspondence with the insurance company about pending prior
authorization if requested (ie. Additional information required for completed of
prior authorization)
•

Date of approval or denial (if approved, prior authorization completed)
o If denied, the reason for denial was collected


Date appeal initiated

o Outcome
•

Approval (prior authorization completed)

•

Denial with scheduled Peer to peer consideration
o Outcome

Data Collection Procedures
Data will be collected and stored electronically on an encrypted flash drive. Preimplementation data was collected from a chart review (October 2018-December 2018) and the
office manager collected post implementation data each onsite encounter (January 2019-April
2019). The DNP student did not have direct access to the electronic medical record.
Data Management
No patient sensitive information was shared nor, was sensitive office information shared
during this project. Data from the interviews and observations was stored on an encrypted flash
drive.
Analysis
The scope of this project included analysis of the implementation of a tracking tool and
policy on the completion and tracking of prior authorizations. Time studies were analyzed to
determine if the tracking tool can improve time management for the office manager.
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Resources & Budget
This project was completed by a Doctor of Nursing Practice student who donated time for
the completion of the project. Time with the office manager, physician, and insurance company
representatives for assistance with policy creation and evaluation of implementation was
required.
The average salary for an addiction medicine physician is $150 an hour (neuvoo.com,
2019). An office manager’s average salary is $18.00 an hour (PayScale, N.D.). The American
Medical Association (AMA) reported in 2015 that on average, a physician will work an hour a
week on prior authorizations, nursing works 13.1 hours per week, and clerical staff works 6.3
hours per week. This clinic does not have nursing support so all of the requirements fall on the
physician and the office manager (AMA, 2015).
A phone call to complete a prior authorization for buprenorphine with Medicaid can take
an average of 15-30 minutes depending on hold time. The process for completion of a prior
authorization for the extended release injectable buprenorphine starts with paperwork that goes
to the drug manufacturer and takes an average of 15-30 minutes to complete. After the drug
manufacturer completes the benefit investigation, the insurance company then respond with the
request for the prior authorization. This process takes an average of 30 minutes to either
complete the paperwork or initiate the prior authorization over the phone. If the insurance
company requires additional information, the data collection can take 15-30 minutes to collect
and to fax the information back. All of these steps of a prior authorization can be completed by
the office manager. If an appeal with a peer to peer is required, the office manager is no longer
able to assist and the physician must complete the process. One peer to peer was required during
the implementation and took 30 minutes. In one day, the prior authorization process can take up
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a significant amount of the office manager’s time
Timeline
The proposal was defended on January 14, 2019. At the time of the proposal, the office
manager and physician announced that they were transitioning the practice to a hospital system
but the time frame was not known. This changed the proposed timeline to include de-identified
information from the patients’ medical record regarding prior authorizations and approvals rather
than a 28-day pre intervention observation period. The tracking tool and policy were
implemented, and a 28-day observation period took place for comparison. The projected
completion date was moved up due to the “soft” closure of the office and the need to delay
starting new patients on buprenorphine.
Methods
A process was created with the goal to decrease the amount of time between drug
prescription to actual administration. The office currently uses an online documentation
software for patient tracking and additional information was added to the patient’s flowsheets for
communication between the office manager and the physician. The office manager also kept a
tickler system for patients starting new drugs that were undergoing the process of obtaining the
prior authorization in the form of a paper chart. The paper chart became the tracking system as
all of the interactions with the insurance company were kept in the paper chart. The office
manager also was able to keep documentation that was sent to the insurance company for
reference when she made phone calls.
Intervention
During the organizational assessment, the office manager stated that she did not have
experience working with the insurance industry. When buprenorphine/naloxone in films were
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first being prescribed by the physician, every insurance company required a prior authorization.
The companies would allow her to complete the process over the phone and, for the most part,
give an approval by the end of the phone call. When the physician began to prescribe the
extended release injectable buprenorphine, the insurance company did not provide approvals
over the phone. A new process for completion and tracking of prior authorizations was needed.
1. The process for prior authorization completion was observed and chart reviews were
completed to evaluate current state.
2. Policy was drafted with the help of the office manager (See figure XXX). With the
limited resources available to the office, the manager was instrumental in drafting the
policy to ensure that the proposed intervention was doable. A tickler system was chosen
to ensure ease for follow up. This tickler system was in the form of a paper chart. This
allowed the office manager to keep all of the correspondence with the drug manufacturer,
insurance company, and the patient in one place. The charts were reviewed regularly and
kept in the filing system for pending prior authorizations until approval was obtained. A
policy was created to reflect the process. The policy reflected the protocol to be followed
and was updated as information was received by the insurance companies.
3. Policy was implemented to reflect this process: New patients to the practice that are in
withdrawal from an opioid are started on Suboxone. At the completion of the first
appointment, the patient leaves the office with a prescription. If the patient has Medicaid,
the office manager calls, and the prior authorization is completed. The drug is authorized
prior to the patient leaving the office. Some of the private insurance companies that the
physician accepts have added buprenorphine/naloxone to their formularies and they no
longer require prior authorization and the patient will be able to fill their prescription
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after their visit. Of the private companies that still require a prior authorization, a call
will be made to initiate and complete (if possible) the prior authorization.
After a patient is stable on buprenorphine/naloxone at the approved dose per the
manufacturer’s guidelines, the physician and patient may decide to transition to the
extended release injectable buprenorphine. The physician communicates this change to
the office manager who initiates the benefit investigation with Indivior, the drug
manufacturer. The patient is provided with the drug information and the contact
information for Indivior as the patient will be contacted to review their insurance and
possible program assistance for drug coverage. After the benefit investigation is
completed, Indivior contacts the office with their findings regarding co-pays and
assistance programs. If a call is not received by Indivior in a timely manner, the office
manager will call for an update. This benefit analysis also provides the office with the
information regarding which specialty pharmacy is to be used for dispensing of the
medication. The office manager can then initiate the prior authorization with the
insurance company. A tickler system is in place to contact the private insurance
companies once to twice weekly depending on the patients proposed date to start the long
acting injectable buprenorphine. If the patient has Medicaid, the benefit investigation is
not required, and the office manager initiates the prior authorization.
4. Data was collected with the help of the office manager. This data included preintervention data with dates into the fall of 2018.
Approach
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The impact of the intervention was assessed using pre and post intervention data.

Through observation and patient chart review with the office manager, de-identified information
was gathered and reviewed.
Measures
Time frames from start of prescription to the actual start of treatment were measured. A
tickler system was used by the office manager to track the prior authorization process. Other
data collected included medication that was prescribed, insurance company, dates of
correspondence with the insurance company, and approval/denial date. If denied, additional
information was collected to include the reason for denial, appeal start/end dates and final
outcome of appeal if appropriate.
Analysis
Time frames were compared pre project initiation and post intervention.
Ethical Considerations
The DNP project was submitted to the Grand Valley State University Human Research
Review Committee for institutional board determination (IRB) and was determined to be nonresearch (see Figure 4). The organization did not require a formal presentation for the ethics
review board. All data analyzed was de-identified of any patient sensitive information.
Results
This project took place in 3 phases. Evaluation of the current state, implementation of
new processes and evaluation of the future state. All data was collected with the assistance of
the office manager as the DNP student did not have access to the electronic medical record.
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Current state
Chart reviews were completed with the office manager during the time frame of October
1, 2018 through December 31, 2018. This review was completed to enable comparison to the
new process. During the described timeframe, the physician had six new patients present to the
office. Of those patients, four were started on buprenorphine/naloxone films. Their insurance
coverage consisted of: Two self-pay, one Blue Cross Blue Shield, one Medicaid and two
Priority Health. The office manager reported that the only prior authorization that had to be
completed during this time was for the patient with Medicaid. She reports that with the changes
in the insurance formularies, buprenorphine/naloxone has been covered without the need for
prior authorization (Personal communication, XXX, April, 2019).
Implementation
Implementation of the tracking/tickler system took place after the proposal was defended
in January. Prior authorizations for the extended release injectable buprenorphine that were in
process were included in the data collection if the approval was not received. The office
manager implemented using the patients’ paper charts as her tracking system for the prior
authorizations. This allowed the office manager to keep all paperwork in one place separated out
by patient.
Post Implementation
The physician had five patients that were successfully transitioned from
buprenorphine/naloxone to an extended release injectable buprenorphine. Two of the patients
had State of Michigan Medicaid, one patient had Blue Cross Blue Shield (BCBS) of Michigan,
another had United Health Care and the last patient had Priority Health insurance. The patients
with Medicaid were approved to start the extended release injectable buprenorphine within two
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weeks of their prescription being written with a mean time of 15 days. The patient with BCBS,
the approval time was nearly six weeks (38 days). The first prescription was written at the end
of November. BCBS responded requesting additional information which was provided to them.
The first injection was authorized in early January and administered soon after. The patient with
Priority Health had a similar authorization time. The request started the third week of December
2018 with Priority Health requesting additional information in early January with a final
approval at the end of January 2019 (42 days). The office manager, using a tickler system called
these insurance companies twice weekly to get updates and to try to expedite the process with no
success. United Health Care gave the office manager the most trouble with obtaining the prior
authorization. The process started the third week of December 2018 and required multiple faxes,
a peer to peer phone call, and finally, a call to the medical director. The patient was finally given
the first injection in early February 2019 (49 days). The patient with United Health Care
required an additional prior authorization when the dose changed from 300mg of the injectable
buprenorphine to the 100mg maintenance dose. The prior authorization process was initiated in
mid- March 2019 and as the completion of the data collect, the prior authorization was still
pending.
Discussion
When discussing the situation with the office manager, it became apparent that changes
in the time frame between the initial prescription and the start of treatment happen because of
changes in formularies with the insurance company. In the spring of 2018, most insurance
companies required a prior authorization for buprenorphine/naloxone. By January of 2019, few
insurance companies required a prior authorization. For those that did, the office manager was
able to complete the process over the phone with same day approval that was good for one year
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from the date of request. The office manager found that her process truly did not change, but the
change in formulary, shortened the time between prescribing and starting treatment (XXX, April
4, 2019). A significant issue, each insurance company has it own requirements for medication
assisted treatment for opioid addiction.
Priority Health lists that they require a prior authorization for buprenorphine/naloxone or
the extended release injectable buprenorphine. Buprenorphine/naloxone is a Tier 1 medication
which means that the medication is available in generic form and cost less. Priority Health limits
the amount of buprenorphine/naloxone they will prescribe each month and they will not cover
any other opioids for a patient that is receiving buprenorphine/naloxone. In contrast, the
extended release injectable buprenorphine is a Tier 7 medication which is a medical benefit
specialty medication. This means that the prescription drug program does not cover this
medication and the medical benefit makes the determination. Priority Health requires that the
extended release injectable buprenorphine be filled at one of their approved specialty pharmacies
(Priority Health Approved Drug List, 2019).
Blue Cross Blue Shield of Michigan does not require a prior authorization for
buprenorphine/naloxone as of the latest clinical drug list update (April 2019). The extended
release injectable buprenorphine is not listed as being covered or not covered. When a call was
made to the insurance company, the representative stated that the drug may be covered with
certain plans that they offer. The representative did not reflect which plans would cover the
medication (XXX, personal communication, April 11, 2019).
United Health Care provides a policy online regarding the long acting injectable
buprenorphine (Sublocade®) and combination buprenorphine/naloxone (Suboxone®) coverage.
For buprenorphine/naloxone, an authorization is provided for 3 months for patients on 24mg
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daily. After that time frame, if the patient requires the same dose, the physician must provide a
rationale for exceeding the maximum dose set by United Health Care and the patient must fail a
trial of the plans accepted dose. This policy could be dangerous to patients undergoing treatment
for addiction. This could result in treatment delays and relapses. The prescribing information
for buprenorphine/naloxone states that the recommended dose is 16mg, but the acceptable daily
dose is up to 24mg (Suboxone® prescribing information, 2018). If the patient is on 16mg daily
of buprenorphine/naloxone, the authorization from United Health Care will be extended to 12
months.
The policy from United Healthcare on the extended release injectable buprenorphine is
consistent with the drug manufacturer’s guidelines for treatment which states that after a patient
is stable on buprenorphine/naloxone, the patient may be transitioned over to the extended release
injectable buprenorphine. The policy reflects the recommendation for the patient to start on the
300mg dose and after two months, be reduced to the 100mg maintenance dose. The policy goes
on to give guidance for patients that cannot tolerate the lower dose in approving the patient for
the higher dose. The initial approval is to be for 6 months and continuation therapy is to be
approved for 12 months. The difficulty with obtaining the prior authorization from this company
is not understood with such a clear policy in place. United Health Care would only authorize the
extended release injectable buprenorphine based on the dose. The extended release injectable
buprenorphine is administered at 300mg for the first two injections and then the maintenance
dose is 100mg. At the time of this writing, the office manager is still having difficulty getting
the maintenance dose covered for a patient who will be delayed in treatment if not resolved soon.
State of Michigan Medicaid also provides the requirement for authorization online. For
an approval the patient must be on buprenorphine/naloxone or equivalent. The patient is
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provided approvals for six months at a time. Medicaid does further require that patients undergo
urine drug screens every 30 days in addition to treatment counseling. There is no lifetime limit
but extending requests for the extended release injectable buprenorphine are completed on a case
by case basis.
Of interest, in the state of Michigan, the Medicaid program requires that the patient be
dispensed the name brand Suboxone®. The provider cannot write the prescription for the brand
name or request the brand name but when the pharmacy tries to run the claim online for the
patient, a denial is granted since the generic medication is not covered. A special code for
Medicaid patients must be added to the prescription but this information was not forwarded to
dispensing pharmacies or to the provider (personal communication, XXX, March, 2019).
With each company having their own requirements for the approval of these important
medications, it is understandable that the office manager is having difficulty with prior
authorizations. At the American Society of Addiction Medicine conference in April of 2019,
review of the process with other professionals found the same struggles in getting medication
assisted treatment covered with the private insurance companies. Providers that worked
exclusively with state funded Medicaid programs were having success with obtaining
authorizations for some of the newer treatments in a timely manner.
To place all the blame on the insurance industry would not be fair. The current pricing of
the medications as set by the drug manufacturer is a limitation to many insurance companies
placing the drugs on their formularies (Wang, 2018). It has been noted the drug prices greatly
exceed the clinical benefit for new treatments thus making it difficult to easily prescribe to
patients (Wang, 2018).
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Limitations
A limitation to this project was that the physician accepted a position to work with a

hospital system which resulted in a soft closure of the practice. Patients were being seen off-site
until the physician was able to start with the new organization which limited the physician in
being able to continue prescribing the extended release injectable buprenorphine due to DEA
requirements for delivery and administration of the drug. The physician continued her current
patients on their medications, but no new patients were accepted during the period of transition
to the new hospital system. Another limitation is the measures used have no reliability or
validity. A significant limitation to this study is its dependence on a third party which was the
insurance industry for the success or failure when the third party was not aware. An additional
limitation to this study was that the physician was newly prescribing injectable buprenorphine
and much of the pre intervention data is related to the prescribing of buprenorphine/naloxone
which was noted to be added to some of the private insurance company’s formulary, thus
skewing the data.
Implications for Practice and Further Study in the Field
This DNP project has multiple practice implications. The insurance industry can have a
significant effect on patients’ success or failure with treatment for addiction. It shouldn’t be
easier to obtain opioids through the insurance industry than the treatment that helps patients get
off opioids. With the current opioid crisis, something needs to change when it comes to
authorization of these medications.
Conclusion
The United States is currently experiencing an emergency when it comes to the opioid
crisis. People are dying every day due to overdose when treatment is available. This treatment
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should not be difficult to obtain. The insurance industry requiring prior authorization is
understandable. The medications have requirements for prescribing but long turn around times

for the prior authorizations are not appropriate. Attempting to provide a resource to the clinic to
improve the time frame from the time the prescription is written until the patient is able to start
the medication did not help. Changes in formularies at the level of the insurance companies can,
and have in the past, help. It is unfortunate that people are dying when medication assisted
treatment is available.
Dissemination of Results
The results have been reviewed with the physician and the office manager but will be
formally reviewed with the Grand Valley State University faculty that participated with this
project at the Dissemination Defense in late July. These results were informally discussed with
professionals in addiction medicine at the American Society of Addiction Medicine conference
in early April 2019. These results will be uploaded to Scholar works.
Reflection on DNP Essentials
The American Association for Colleges of Nursing (AACN) requires that all DNP
students meet the eight essential competencies in order to graduate (AACN, 2006). “The DNP
essentials exemplify thoughtful contribution and roadmap of the competencies that nursing
scholar must exemplify to have an impact on health care from a nursing perspective” (Moran,
Burson & Conrad, 2017). These essentials were met through the clinical portion of the DNP
program and through the scholarly project.
I. Scientific Underpinnings for Practice
The AACN adopted a definition of nursing science as “an entity in itself with a growing
body of scientific knowledge, while acknowledging the value of incorporating knowledge from
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other sciences” (Zaccagnini & White, 2017, p. 6). This is the foundation of knowledge for
nursing practice. In the completion of the project, gaining an understanding of the effects of
withdrawal made the project more important. While the project has an outward appearance of
being related to getting treatment paid for timely, it truly has an even more important role in
continuation of treatment for a vulnerable population.
II. Organizational and Systems Leadership for Quality Improvement and Systems
Thinking
Zaccagnini & White stated that “the advanced practice nurse must be able to discern
issues quickly and effectively and contribute to strategic energy and system redesign” (2017, p.
43). In the completion of this project, the goals remained the same while trying to adjust to the
ever-changing world related to the insurance industry. This addiction medicine field is getting a
lot of attention at this time related to the opioid crisis and the insurance industry is adjusting their
formularies to reflect the urgency, some better than others. In medicine, change will be constant
as research continues to show that we can improve in our treatment of patients. Improving
processes to reflect the changes will be necessary to be successful in the field.
III. Clinical Scholarship and Analytical Methods for Evidence-Based Practice
“In advanced practice, scholarship should be integrated with practice a purposeful,
systematic, and conscious endeavor. The emphasis is on inquiry, outcomes, and evidence to
support practice” (Zaccagnini & White, 2017). Being able to review the literature for high level
evidence was important in the completion of this project. In addiction medicine, a lot of expert
opinion is printed in the literature and presented as being evidenced-based. As a DNP prepared
nurse, this information is able to be reviewed and analyzed prior to implementing into practice.
This is a critical step in quality improvement.
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IV. Information Systems/Technology and Patient Care Technology for the Improvement
and Transformation of Health Care
For the DNP-prepared advanced practice nurse, the use of technology is essential. From
the electronic medical record to the wireless communication devices, the DNP-prepared nurse
needs to be up to date and be able to effectively use the devices for the best patient outcomes
(Zaccagnini & White, 2017). In the clinic that this project took place, the physician provides
care to patients in rural southern Michigan through tele-health. While tele-health was outside of
the scope of this project, the DNP student was able to observe the process for seeing patients in
this capacity. In addition, the DNP student was able to observe an informatics nurse at a large
hospital system for a day to learn about their role.
V. Health Care Policy for Advocacy in Health Care
“There are three critical ingredients to democratic renewal and progressive change in
America: good public policy, grassroots and organizing and electoral politics” (Paul Wellstone
as quoted by Zaccagnini & White, 2017, p.189). This essential was met when at the Michigan
Nurse Practitioner Advocacy Day. This day provided the opportunity for students and practicing
providers to meet with their representatives and senators to discuss what nurse practitioners are
trained to do, and where the limitations are regarding providing care to patients. In addition, a
luncheon was attended with the office physicians and a selection of local state representatives
and senators to discuss the issue of prior authorizations and medication assisted treatment.
VI. Interprofessional Collaboration for Improving Patient and Population Health
Outcomes
The professions in nursing and in medicine agree that interprofessional collaboration is
needed and have even went on to acknowledge that “the future of healthcare delivery requires

FINAL DEFENSE

43

interprofessional teams that are prepared to meet the diverse, multifaceted health issues of the
population” (Zaccagnini & White, 2017, p. 235). In addiction medicine, the physician is assisted
with the treatment of the patients by psychiatry, social work, counselors, and primary care. One
provider cannot bring all the necessary components together for the treatment of this population.
Working together brings about the best patient outcomes.
VII. Clinical Prevention and Population Health for Improving the Nation’s Health
In the completion of a preceptor led clinical experience, this essential was met. The
physician provided care to a rural community that was evidenced-based. The DNP student was
trained to view the current health maintenance due on every patient regardless of the reason of
the visit to the practice. It was felt that many times, patients will only come into the practice
when not well and it may be the only opportunity to approach health maintenance with them. It
was noted that during many of these visits, patients were given their influenza vaccinations or
screening studies were ordered for the patient. The scholarly project also provided a view into
the prevention of the disease of addiction. The physician speaks in many different arenas to
teach the community about prevention rather than the care that she provides.
VIII. Advanced Nursing Practice
“The DNP-prepared nurse practitioner will continue to provide health care through
assessment, diagnosis, and treatment of the complex responses of individuals, families, or
communities to actual or potential health problems, prevention of illness and injury, maintenance
of wellness, and provision of comfort” (ANA, 2010 as cited by Zaccagnini & White, 2017, p.
339). This essential was met in the clinical portion of the DNP program in addition to during the
scholarly project. The clinical opportunities taught me to assess, diagnose, and treat illness in
addition to other opportunities in which wellness was promoted. While no patient contact took
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place during the scholarly project, the DNP student was in the background working toward
getting medications covered so that the patient would not be denied their treatment and treatment
was continued and not segmented based on prior authorizations.
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Appendix
Figure 1. Burke-Litwin Model
The Burke-Litwin Model of Organizational Performance and Change

Figure 1. A model of organizational performance and change. Reprinted from “A Casual Model
of Organizational Performance and Change,” by Burke and Litwin, 1992, Journal of
Management, 18, 528. Copyright 1992 by Southern Management Association
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Figure2. Flow Diagram of search selection process (Prior Authorization)

Identification

PRISMA 2009 Flow Diagram

Records identified through
database searching
(n = 15)

Eligibility

Screening

Records after duplicates removed
(n = 15 )

Records screened
(n = 15)

Records excluded
(n =3)

Full-text articles assessed
for eligibility
(n = 12)

Full-text articles excluded,
with reasons
(n = 8)

Included

Studies included in
qualitative synthesis
(n = 4)

Studies included in
quantitative synthesis
(meta-analysis)
(n =0)

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS
Med 6(7): e1000097. doi:10.1371/journal.pmed1000097
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Figure 3. SWOT Analysis of New Mental Health Organization in West Michigan
•
•
•
•
•

•
•
•
•
•

•

•

Strength
Physician is passionate about her
calling
Opioid epidemic is a popular topic
right now (political)
Office Manager and Physician are
related and live in the same home.
Patient referral source is expanded
related to off-site organization and
tele-health
EMR for off-site organizations has
access to templates to ensure that all
categories are documented for
reimbursement.
Off-site reimbursement for physician
and office manager paid hourly, not by
the patient.
Service is a significant need at this
time.
Opportunities
Create policy and procedures to
protect both the patient and physician.
Hire an advanced practice provider to
assist the physician in providing care
and taking after hour call.
Change how appointments are
scheduled (only give the patient the
arrival time, not the actual time
scheduled with the provider)
Use EMR in the clinic to the fullest
capacity for improved time
management, insurance/billing
reimbursement, and consistency.
Use of G-Suite through Google for
patient treatment records and account
information. (Increased security that is
HIPAA compliant)

•
•
•
•
•
•

•
•

•

•

Weaknesses
Office Manager and Physician are
related and live in the same home.
No Policy and Procedures in plan
One Physician- no back up
Billing (for patients evaluated in the
clinic) is not consistent
EMR in clinic is not possibly being
used to it’s full capacity related to
templates for appropriate billing.
Many patients are on Medicaid and
the reimbursement is limited for these
clinic patients

Threats
New Physicians in the area that
provide similar care
Popular topic in this day and age with
training available for providers to give
this type of care without referral to the
clinic.
Changes to the affordable care act
may restrict access for patients with
mental health concerns, including
addiction.
Google Document not HIPAA
compliant and at risk for compromise
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Figure 4. IRB Determination
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Figure. XXX
Insurance Coverage
Month
October

November
December
January
February
March

Drug Prescribed
Buprenorphine/naloxone
SQ Buprenorphine
Buprenorphine/naloxone
SQ Buprenorphine
Buprenorphine/naloxone
SQ Buprenorphine
SQ Buprenorphine
Buprenorphine/naloxone
SQ Buprenorphine
Buprenorphine/naloxone
Buprenorphine/naloxone
Buprenorphine/naloxone
SQ Buprenorphine

Insurance Company
Self pay
Medicaid
Medicaid
Medicaid
Priority Health
BCBS
Medicaid
Self pay
Priority Health
United Healthcare
BCBS
BCBS
United Healthcare

INSURANCE COMPANY
Medicaid

Blue Cross Blue Shield

Self pay

Priority Health

10%

20%

40%

30%

PA required?
N
Y
Y
Y
N
Y
Y
N
Y
N
N
N
Y
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Figure XXX.
Date PA
initiated
10/17/18

Drug

Insurance
Company
Buprenorphine/naloxone Medicaid

Date of Ins
Decision
10/17/18

10/29/18

SQ Buprenorphine

Medicaid

11/14/18

10/29/18

SQ Buprenorphine

Medicaid

11/16/18

11/28/18

SQ Buprenorphine

BCBS

1/4/19

12/19/18

SQ Buprenorphine

2/6/19

12/20/18

SQ Buprenorphine

United
Healthcare
Priority Health

3/15/19

SQ Buprenorphine

United
Healthcare

N/A

1/31/19

Decision
Approved for
6 months
Approved for
6 months
Approved for
6 months
Approved for
6 months
Approved for
300mg dose x2
Approved for
6 months
No decision as
of 4/1/19patient due for
100mg dose
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Figure XXX. Policy and Procedure
Policy Name:
Date last reviewed:
Approval or last revision:

Completion of Prior Authorizations for
Medication Assisted Treatment.

Approved by:
POLICY
Prior authorizations will be completed in a timely manner to ensure timely initiation and/or continuation of
medication assisted treatment for patients.
SCOPE
This policy applies to staff of The XXX Center.
PROCEDURES
1. New patients to the practice that are in withdrawal from an opioid and found to be appropriate for treatment by
the physician are started on Suboxone. At the completion of the first appointment, the patient leaves the office
with a prescription. If the patient has Medicaid, the office manager calls, and the prior authorization is completed.
The drug is authorized prior to the patient leaving the office.
2. After a patient is stable on buprenorphine/naloxone at the approved dose per the manufacturer’s guidelines,
the physician and patient may decide to transition to the extended release injectable buprenorphine.
• The physician communicates this change to the office manager who initiates the benefit investigation
with Indivior, the drug manufacturer.
• The patient is provided with the drug information and the contact information for Indivior as the patient
will be contacted to review their insurance and possible program assistance for drug coverage.
• After the benefit investigation is completed, Indivior contacts the office with their findings regarding copays and assistance programs. If a call is not received by Indivior in a timely manner, the office manager
will call for an update. This benefit analysis also provides the office with the information regarding which
specialty pharmacy is to be used for dispensing of the medication.
• The office manager can then initiate the prior authorization with the insurance company.
•
A tickler system, in the form of a paper chart, is in place. The system is to remind the staff member to
contact the private insurance companies once to twice weekly depending on the patients proposed date
to start the long acting injectable buprenorphine.
•
If the patient has Medicaid, the benefit investigation is not required, and the office manager initiates the
prior authorization.
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Table Articles included in review with author, year, purpose, design, inclusion, results, conclusions
Author (Year) Design (N)
Inclusion
Purpose
Criteria
Reif,
Correlational Telephone
Creedon,
study
survey
to
health
plan
Horgan,
Stewart
&
executives
Garnick
and/or patients
(2017).
receiving care
for opioid use
disorder.
AndrakaQualitative
Physicians had
Christou
&
to be licensed
Capone
as a physician
(2018)
in the United
States

Intervention vs
Results
Comparison
Comparison
With the “leveled” playing field(before/during/after the reduced disparities in coverage
implementation of the for mental health it was hopeful
affordable care act)
that significant changes would be
noted in the coverage for opioid
use disorder. This was not the
case
Comparison

Physicians in the addiction
medicine field were interviewed
regarding barriers to treating
patients with opioid use disorder.
The findings were consistent
across the sample.

Andrews,
Systematic
Abraham,
Review
Grogan,
Westlake,
Pollack
&
Friedmann
(2019)

Comparison
(assessment
of
2
utilization restrictions
imposed
on
buprenorphine benefits)

Found that many providers will
not prescribe buprenorphine
related to the burdensome process
related to prior authorizations.
Another tactic that providers felt
was being used by the insurance
industry was annual limits which
would deter the provider in
providing buprenorphine as it was
known that the provider would

Treatment
facilities that
accept
Medicaid for
reimbursement.

Conclusion
Insufficient
coverage
for
patients with opioid
use disorder

Limited insurance
reimbursement/
regulatory
restrictions
for
treatment/restricted
access
for
medication assisted
treatment.
Some providers are
hesitant
to
prescribe
buprenorphine
related to the tactics
used
by
the
insurance industry
(prior
authorizations and
annual limits)
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Mark, Lubran, Systematic
McCanceReview
Katz, Chalk &
Richardson
(2015)

Pharmacy
(medication
assisted
treatment)

Comparison
of
utilization data for state
Medicaid programs

Clark, Baxter,
Barton,
Aweh,
O’Connell &
Fisher (2014)

Patients with
Medicaid
insurance
coverage and a
diagnosis
of
opioid
use
disorder

Effects of the insurance
companies requirement
that
buprenorphine/naloxone
be dose reduced to 16mg
for patients that were
stable on 24mg.

have to change the medication
shortly
Many state Medicaid programs
require coverage of medication
assisted treatment but yet require
a variety of techniques that can
make
coverage/prescribing
difficult
The dose reduction requirement
did not save a significant amount
of money for the insurance
industrypatients
relapsed
initially but were noted to be
stable on their treatment within 3
months

States need to reexamine
their
substance
use
disorder benefits.
Lower doses of the
medication did not
save
the
state
money but it was
thought that the
decreased
dose
decreased diversion
of the medication.
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